Glucagon-like peptide 1 receptor agonists, more commonly known as GLP-1 medications, have dominated headlines for their ...

Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.

GLP-1 supplement makers claim that their products work similarly to weight loss injections like Ozempic. Here's what experts ...

Research shows patients taking weight-loss drugs like Ozempic and Wegovy are more likely to have food left in the stomach or ...

In real-world settings multiple factors contribute to non-persistence, including adverse effects, high cost-sharing and ...

Agents like semaglutide show promise for treatment of substance use disorders. Inaccessibility of GLP-1 agonists due to high ...

"There is a clear association between the use of GLPs and increased risks of food retention during upper endoscopy," Mathur ...

Folks who take one of the popular GLP-1 weight-loss meds might end up with a cancelled endoscopy or colonoscopy New research ...

People with type 2 diabetes and obesity who develop kidney disease may benefit more from bariatric surgery than from GLP-1 ...

The quest for effective and safe weight loss solutions has long been a focus of medical research. In recent years, a novel ...

Tirzepatide, a dual GIP and GLP-1 receptor agonist, has gained widespread recognition for its effectiveness in promoting substantial weight loss by enhancing metabolic functions and controlling ...